261 related articles for article (PubMed ID: 9987777)
1. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
3. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
[TBL] [Abstract][Full Text] [Related]
4. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Roser HW; Bockisch A
Thyroid; 2001 Jul; 11(7):647-59. PubMed ID: 11484893
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
6. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue.
Robbins RJ; Hill RH; Wang W; Macapinlac HH; Larson SM
Thyroid; 2000 Feb; 10(2):177-83. PubMed ID: 10718556
[TBL] [Abstract][Full Text] [Related]
9. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
10. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
[TBL] [Abstract][Full Text] [Related]
11. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
12. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor scintigraphy in non-medullary thyroid cancer.
Postema PT; De Herder WW; Reubi JC; Oei HY; Kwekkeboom DJ; Bruining HJ; Bonjer J; van Toor H; Hennemann G; Krenning EP
Digestion; 1996; 57 Suppl 1():36-7. PubMed ID: 8813465
[TBL] [Abstract][Full Text] [Related]
14. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.
Garin E; Devillers A; Le Cloirec J; Bernard AM; Lescouarc'h J; Herry JY; Reubi JC; Bourguet P
Eur J Nucl Med; 1998 Jul; 25(7):687-94. PubMed ID: 9662589
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
Gulec SA; Serafini AN; Sridhar KS; Peker KR; Gupta A; Goodwin WJ; Sfakianakis GN; Moffat FL
J Nucl Med; 1998 Feb; 39(2):243-5. PubMed ID: 9476928
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
17. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
18. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies.
Lincke T; Singer J; Kluge R; Sabri O; Paschke R
Thyroid; 2009 Apr; 19(4):381-9. PubMed ID: 19355828
[TBL] [Abstract][Full Text] [Related]
19. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
20. [Accumulation of radioactivity in the lung after 111In-octreotide scintigraphy].
Schleicher UM; Cremerius U; Schubert H
Rofo; 1998 Apr; 168(4):404-6. PubMed ID: 9589108
[No Abstract] [Full Text] [Related]
[Next] [New Search]
